Application Information

Application Number : 2025/013873

Application Date : 15-05-2018

Application Type : EPC Fasikül

Grant Number : 2025-GE-627334

Grant Date : 25-09-2025

Registration Number : 2025 013873

Registration Date : 2025-10-21

Protection Type : Patent

European Patent Publication Number (B1) : EP3624837B1

European Patent Application Number : EP18730518.0

Applicants

Person No	Name	Address
7923793	FIVE PRIME THERAPEUTICS, INC.	111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CA 94080 A.B.D.

Inventors

Person No	Name	Address
7923789	Helen L COLLINS	111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080 A.B.D.
7923792	Xiang ZHANG	111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080 A.B.D.
7923791	Hong XIANG	111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080 A.B.D.
7923790	James HNATYSZYN	111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080 A.B.D.

Invention Information

Name Of Invention	KANSER TEDAVİSİNDE KEMOTERAPİ AJANLARI İLE KOMBİNASYON HALİNDEKİ ANTİ-FGFR2 ANTİKORLARI
Summary Of Invention	Bu başvuru, mFOLFOX6 kemoterapi ile birlikte belirli kanserlerin tedavisinde FGFR2 izoformu FGFR2-IIIb'ye (FGFR2b olarak da bilinir) karşı antikorlar dahil olmak üzere fibroblast büyüme faktörü reseptörü 2'ye (FGFR2) karşı antikorların kullanımıyla ilgilidir.

Attorney Information

Name	TOLGA ÇAYLAK DIŞ PATENT MARKA TESCİL ve DANIŞMANLIK HİZ. LTD. ŞTİ.
Address	GİRNE MAH. ELİFLİ SOK. NO:27 BAY PLAZA KAT:5-6-7 MALTEPE/ İSTANBUL

Priority Information

Date of Priority	Priority Number	Country of Priority
16-05-2017	US 201762507053P	US
06-11-2017	US 201762581992P	US

Classes of The Invention

Patent Application Procedures

Date	Date of Notification	Operation	Document
	17-10-2025	Şekli Kontrol Yapıldı. Başvuru / İstem / Fasikül Onaylandı.
24-09-2025		EPO'dan Gelen Patent Fasikül

Publications

Publication Date	Description
21-10-2025	Avrupa Patent Fasiküllerinin İlanı

Payment Dates

Row	Year	Payment Date	Amount Paid (₺)